Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Syros Pharmaceuticals revenue
Syros Pharmaceuticals's revenue is $9.9 million.
What is Syros Pharmaceuticals's revenue?
- Syros Pharmaceuticals's revenue growth from 2015 to 2023 is 3,034.38%.
- Syros Pharmaceuticals has 124 employees, and the revenue per employee ratio is $80,129.
- Syros Pharmaceuticals's peak quarterly revenue was $7.8M in 2021(q4).
- Syros Pharmaceuticals peak revenue was $23.5M in 2021.
- Syros Pharmaceuticals annual revenue for 2022 was 14.9M, -36.65% growth from 2021.
- Syros Pharmaceuticals annual revenue for 2023 was 9.9M, -33.23% growth from 2022.
On this page
Zippi applies for you, and finds you a job.
Syros Pharmaceuticals historical revenue
Syros Pharmaceuticals's peak revenue was $23.5M in 2021. The peak quarterly revenue was $7.8M in 2021(q4).
Syros Pharmaceuticals's revenue increased from $317.0k in 2015 to $9.9M currently. That's a 3,034.38% change in annual revenue.
Syros Pharmaceuticals annual revenue
Syros Pharmaceuticals annual revenue over time
| Fiscal year / year | Syros Pharmaceuticals revenue |
|---|---|
| 2015 | $317,000 |
| 2016 | $317,000 |
| 2017 | $1.1M |
| 2018 | $2.1M |
| 2019 | $2.0M |
| 2020 | $15.1M |
| 2021 | $23.5M |
| 2022 | $14.9M |
| 2023 | $9.9M |
How accurately did Syros Pharmaceuticals' revenue projections match actual performance?
Syros Pharmaceuticals annual growth
Syros Pharmaceuticals saw the greatest revenue growth in 2020, when revenue increased by 661.5%.
Syros Pharmaceuticals had the lowest revenue growth in 2022, when revenue changed by -36.65%.
Syros Pharmaceuticals annual growth rate over time
| Year | Syros Pharmaceuticals growth |
|---|---|
| 2016 | 0%↓ |
| 2017 | 247%↑ |
| 2018 | 86%↑ |
| 2019 | -3%↓ |
| 2020 | 662%↑ |
| 2021 | 56%↑ |
| 2022 | -37%↓ |
| 2023 | -33%↓ |
Syros Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Syros Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2016 | - | - | - | $316,815 |
| 2017 | $1.1M | - | - | - |
| 2018 | $370,000 | $375,000 | $412,000 | $893,000 |
| 2019 | $454,000 | $462,000 | $558,000 | $508,000 |
| 2020 | $2.4M | $3.2M | $3.8M | $5.7M |
| 2021 | $4.8M | $5.2M | $5.7M | $7.8M |
| 2022 | $5.5M | $6.3M | $3.9M | ($754.0K) |
| 2023 | $3.0M | $2.8M | $3.8M | $386,000 |
Syros Pharmaceuticals jobs nearby
Do you work at Syros Pharmaceuticals?
Did Syros Pharmaceuticals meet its revenue projections?
Syros Pharmaceuticals financing
Syros Pharmaceuticals received early financing of $30.0M on 2013-04-11.
| Series | Round size | Date |
|---|---|---|
| Series A | $30M | 04/2013 |
| Series B | $53M | 10/2014 |
| Series C | $40M | 01/2016 |
| Post Ipo Equity | $35M | 04/2017 |
| Post Ipo Equity | $11.4M | 01/2018 |
| Debt Financing | $60M | 02/2020 |
| Post Ipo Equity | $90.5M | 12/2020 |
| Post Ipo Equity | $75.6M | 01/2021 |
Syros Pharmaceuticals investors
| Investors | Security type |
|---|---|
| ARCH Venture Partners | Series A |
| Flagship Pioneering Inc | Series A |
| Polaris Partners | Series B |
| Redmile Group | Series B |
| Alexandria Venture | Series B |
| ARCH Venture Partners | Series B |
| WuXi Healthcare Ventures | Series B |
| Flagship Pioneering Inc | Series B |
| Aisling Capital | Series B |
| Polaris Partners | Series C |
| Redmile Group | Series C |
| Alexandria Venture | Series C |
| Deerfield | Series C |
| WuXi Healthcare Ventures | Series C |
| FMR Co. | Series C |
| Casdin Capital | Series C |
| Aisling Capital | Series C |
| Oxford Finance LLC | Debt Financing |
| EcoR1 Capital LLC | Post Ipo Equity |
| Ally Bridge Group | Post Ipo Equity |
| PRAKASH CHAINANI MBA (FINANCE) CMA LIFE SCIENCES US CFO | Post Ipo Equity |
| Omega Funds | Post Ipo Equity |
| OrbiMed Advisors | Post Ipo Equity |
| Bain Capital | Post Ipo Equity |
| Samsara BioCapital | Post Ipo Equity |
Syros Pharmaceuticals competitors
Syros Pharmaceuticals's top competitor, Seagen, earned an annual revenue of $2.0B.
Syros Pharmaceuticals's smallest competitor is Arcadia Biosciences with revenue of $5.0M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Blueprint Medicines | - | $508.8M | 495 | - |
| MacroGenics | - | $150.0M | 307 | - |
| Seagen | - | $2.0B | 900 | - |
| Alios BioPharma | - | $15.7M | 75 | - |
| Ophthotech | - | $210.0M | 58 | - |
| Tetraphase Pharmaceuticals | - | $7.4M | 67 | - |
| Mendel Biotechnology | - | $13.0M | 125 | - |
| AnaptysBio | - | $91.3M | 78 | - |
| Arcadia Biosciences | - | $5.0M | 42 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Syros Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Syros Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Syros Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Syros Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Syros Pharmaceuticals. The data presented on this page does not represent the view of Syros Pharmaceuticals and its employees or that of Zippia.
Syros Pharmaceuticals may also be known as or be related to SYROS PHARMACEUTICALS INC., Syros Pharmaceuticals, Syros Pharmaceuticals Inc and Syros Pharmaceuticals, Inc.